Iambic Therapeutics, Inc. (IAM)
| Market Cap | 695.37M |
| Revenue (ttm) | 18.25M +689.4% |
| Net Income | -94.25M |
| EPS | -4.27 |
| Shares Out | 47.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 497,477 |
| Open | 15.40 |
| Previous Close | 15.80 |
| Day's Range | 14.50 - 15.47 |
| 52-Week Range | 14.10 - 25.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 19, 2026 |
About IAM
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop sm... [Read more]
Financial Performance
Financial StatementsNews
Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics today
21:21 EDT Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics (IAM) today
AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO
Shares in Nvidia ($NVDA)-backed cancer-fighting biotech Iambic Therapeutics ($IAM) soared 13% on its first day of trading following its U.S. IPO. The San Diego, California, company, self-described as ...
Iambic Therapeutics opens at $16.15, IPO priced at $16.00
Iambic Therapeutics (IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, priced 9.375M shares at $16.00. The deal priced at the midpoint...
Iambic Therapeutics 9.375M share IPO priced at $16.00
JPMorgan, Jefferies, BofA and Citi are acting as joint book running managers for the offering. The deal priced at midpoint of $15.00-$17.00 target range.
Iambic Therapeutics Registration statement: Registration filing
Iambic Therapeutics filed a registration statement on October 8, 2026, providing details about a securities offering with the SEC.
Small molecule biotech Iambic Therapeutics files for a $100 million IPO
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Iambic Therapeutics IPO Registration Document (S-1)
Iambic Therapeutics has filed to go public with an IPO on the NASDAQ
Iambic Therapeutics Registration statement: Registration filing
Iambic Therapeutics filed a registration statement on September 21, 2026, providing details about a securities offering with the SEC.